Literature DB >> 7720520

Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.

D J Newton1, R W Wang, A Y Lu.   

Abstract

Identifying selective inhibitors of cytochrome P450 isoforms is a useful tool in defining the role of individual cytochrome P450s in the metabolism process. In this study, nine chemical inhibitors were selected based on literature data and were examined for their specificity toward cytochrome P450-mediated reactions in human liver microsomes. Furafylline was a potent, mechanism-based inhibitor for CYP1A2-mediated phenacetin O-deethylation. The probes sulfaphenazole (CYP2C9) and quinidine (CYP2D6) selectively inhibited tolbutamide methylhydroxylation and bufuralol 1'-hydroxylation, respectively. Additionally, the CYP2E1-catalyzed chlorzoxazone 6-hydroxylation was significantly inhibited by diethyldithiocarbamate. Of the CYP3A4 inhibitor probes used, troleandomycin proved to be the most specific for testosterone 6 beta-hydroxylation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7720520

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  67 in total

1.  Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes.

Authors:  Z H Xu; W Wang; X J Zhao; S L Huang; B Zhu; N He; Y Shu; Z Q Liu; H H Zhou
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.

Authors:  K E Kenworthy; J C Bloomer; S E Clarke; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

3.  Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine.

Authors:  O V Olesen; K Linnet
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

4.  In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).

Authors:  X Wen; J S Wang; K T Kivistö; P J Neuvonen; J T Backman
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

5.  Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity.

Authors:  Janet K Coller; Niels Krebsfaenger; Kathrin Klein; Renzo Wolbold; Andreas Nüssler; Peter Neuhaus; Ulrich M Zanger; Michel Eichelbaum; Thomas E Mürdter
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

6.  The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.

Authors:  Janet K Coller; Niels Krebsfaenger; Kathrin Klein; Karin Endrizzi; Renzo Wolbold; Thomas Lang; Andreas Nüssler; Peter Neuhaus; Ulrich M Zanger; Michel Eichelbaum; Thomas E Mürdter
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

7.  Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes.

Authors:  Kyoung-Ah Kim; Jaegul Chung; Dong-Hae Jung; Ji-Young Park
Journal:  Eur J Clin Pharmacol       Date:  2004-09-08       Impact factor: 2.953

8.  Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.

Authors:  Drew R Jones; So-Young Kim; Michael Guderyon; Chul-Ho Yun; Jeffery H Moran; Grover P Miller
Journal:  Chem Res Toxicol       Date:  2010-05-17       Impact factor: 3.739

9.  Sulfaphenazole and α-naphthoflavone attenuate the metabolism of the synthetic cannabinoids JWH-018 and AM2201 found in K2/spice.

Authors:  Krishna C Chimalakonda; Laura P James; Anna Radominska-Pandya; Jeffery H Moran
Journal:  Drug Metab Lett       Date:  2013-03

10.  Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential.

Authors:  Shigeru Furuta; Nobuyoshi Akagawa; Emiko Kamada; Akio Hiyama; Yoshihiro Kawabata; Nobuhiko Kowata; Atsuhiro Inaba; Anne Matthews; Michael Hall; Tadashi Kurimoto
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.